Cerebellar TumorsNCT04463979
Perioperative Evaluation of Cerebellar Tumors
An observational study of Cerebellar Tumors and Brain Tumor, run by Duke University at 1 site in United States.
Trial summary
This is a prospective, cohort study to evaluate the impact of cerebellar functional topography on perioperative outcomes related to cognition and motor ataxia in patients with cerebellar tumors. Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Cerebellar Tumors, Brain Tumor
- What is being tested?
- Impact of Cerebellar Functional Topography on Cognition and Motor Ataxia
- How many people
- 66 participants
- Where
- 1 siteUnited States
- Study dates
- 28 Feb 2021to 17 May 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Thirty-three adult (≥18 years of age) patients with primary cerebellar brain tumors or metastatic brain tumors located in the cerebellum who will undergo surgery for tumor resection, and 33 adult patients with primary non-cerebellar brain tumors or metastatic tumors located in a non-cerebellar brain location who will also undergo surgery for tumor resection will be included in this study. The non-cerebellar brain tumor control group will be included for comparison.
Who may be able to join
- ≥18 years of age
- Patients with primary cerebellar brain tumors or metastatic brain tumors located in the cerebellum who will undergo surgery for tumor resection, OR with primary non-cerebellar brain tumors or metastatic tumors located in a non-cerebellar brain location who will undergo surgery for tumor resection
Who cannot join
- Patients under the age of 18
- Patients with intracranial pathologies (e.g. stroke, vasculitis, infection, developmental anomalies, etc.) outside of the cerebellum
- Non-oncologic cerebellar pathologies (e.g. stroke, vasculitis, infection, developmental anomalies, primary cerebellar ataxias, etc.)
- Patients who are illiterate, are blind, or do not read or understand English
- Patients with a Karnofsky Performance Status score of equal to less than 40
Trial locations and contacts
1 site in 1 country.
United States1 site
Duke University Medical Center
Durham, North Carolina, 27710
About this study
Official title: Perioperative Evaluation of Cerebellar Tumors: Impact of Cerebellar Functional Topography on Cognition and Motor Ataxia
This is a prospective, cohort study to evaluate the impact of cerebellar functional topography on perioperative outcomes related to cognition and motor ataxia in patients with cerebellar tumors.
Read the detailed description
Purpose of the Study: This is a prospective, cohort study to evaluate the impact of cerebellar functional topography on perioperative outcomes related to cognition and motor ataxia in patients with cerebellar tumors.
Primary Aim: The primary aim of this study is to determine if patients with a cerebellar tumor are more likely to test positive for cerebellar cognitive affective syndrome than patients with non-cerebellar tumors. This information will be used to improve perioperative assessment in patients with tumors of the cerebellum.
Secondary Aim: To determine the impact of tumor location and cerebellar functional topography on perioperative outcomes (determined by standard of care neurological evaluation and brain images) in patients undergoing resection of cerebellar tumors. This information will be used to improve perioperative assessment in patients with tumors of the cerebellum.
Study Interventions: Thirty-three adult (≥18 years of age) patients with primary cerebellar brain tumors or metastatic brain tumors located in the cerebellum who will undergo surgery for tumor resection, and 33 adult patients with primary non-cerebellar brain tumors or metastatic tumors located in a non-cerebellar brain location who will also undergo surgery for tumor resection will be included in this study. The non-cerebellar brain tumor control group will be included for comparison. Participants in this study will undergo surgical resection of their cerebellar or brain tumor (as per standard of care), as well as clinical and radiographic assessment, including: neurological physical examination (including Karnofsky Performance Scale (KPS) if conducted per Standard of Care), and magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography, prior to, immediately after, at one-month, 6-month, and 1-year follow-up status post-surgical resection. These data will also be collected at 18-month (±60 days) and 24-month (±60 days) visits post-surgery, if regular office visits with the neurosurgeon are scheduled at these two time points. Only at baseline, the following will be conducted: Brief Ataxia Rating Scale (BARS) assessment score, Cerebellar Cognitive Affective Scale (CCAS/Schmahmann syndrome) scale score, Montreal Cognitive Assessment (MoCA) assessment, and a quality of life (QoL) assessment using the SF-36 questionnaire.
Data analysis: For each test item within the CCAS there is a threshold score allowing a pass/fail determination that differentiates CCAS-positive patients from CCAS-negative patients. The primary, study endpoint is the percentage of patients with a positive CCAS diagnosis prior to surgery. The investigators will evaluate whether CCAS is preferentially seen in association with any demographic or descriptive variables (particularly tumor location in the cerebellum) using chi-squared testing unless otherwise indicated. Demographic data including sex, age at time of brain tumor diagnosis and at surgery, education level completed, and dominant writing hand will be described. The distribution of each of the following preoperative variables will also be described: presenting symptom (cognitive, motor, or vestibular), brain lesion type (newly diagnosed vs recurrent), primary tumor site, primary tumor histology, presence or absence of a systemic burden of disease, presence of hydrocephalus or previous seizure in 30 days prior to surgery, prior surgery, prior whole brain radiation or stereotactic radiosurgery, initiation of antiepileptic or steroids prior to surgery, the indication for surgery. These data will be used to compare baseline characteristic of cerebellar tumor patients with non-cerebellar brain tumor patients. All statistical analysis will be performed by the investigators using Prism 4.0 (GraphPad Software, Inc.) and Stata v10 (StataCorp Lp). Significance will be assessed at alpha = 0.05.
Risks/Benefits: There will be physical or health-related risks to the surgical resection of the patients' cerebellar tumor according to the standard of care. Risk is also involved to the extent that privacy and confidentiality may be compromised. However, every reasonable effort will be made to limit breaches of privacy and confidentiality. Participants will not benefit directly from this study. However, the results of this work will help improve the perioperative assessment of patients with tumors of the cerebellum, which may improve rehabilitation efforts in this unique patient population.
- Conditions
- Cerebellar Tumors, Brain Tumor
- Being tested
- Impact of Cerebellar Functional Topography on Cognition and Motor Ataxia
- Medical subject headings
- Cerebellar Neoplasms, Brain Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Impact of Cerebellar Functional Topography on Cognition and Motor AtaxiaOther
Participants in this study will undergo surgical resection of their cerebellar or brain tumor (as per standard of care), as well as clinical and radiographic assessment, including: neurological physical examination (including Karnofsky Performance Scale (KPS) if conducted per Standard of Care), and magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography, prior to, immediately after, at one-month, 6-month, and 1-year follow-up status post-surgical resection. These data will also be collected at 18-month (±60 days) and 24-month (±60 days) visits post-surgery, if regular office visits with the neurosurgeon are scheduled at these two time points.
Only at baseline, the following will be conducted: Brief Ataxia Rating Scale (BARS) assessment score, Cerebellar Cognitive Affective Scale (CCAS/Schmahmann syndrome) scale score, Montreal Cognitive Assessment (MoCA) assessment, and a quality of life (QoL) assessment using the SF-36 questionnaire.
| Study group | Role | What they receive |
|---|---|---|
| Cerebellar Tumors | Thirty-three adult (≥18 years of age) patients with primary cerebellar tumors or metastatic tumors located in the cerebellum who will undergo surgery for tumor resection. Receives: Other: Impact of Cerebellar Functional Topography on Cognition and Motor Ataxia | |
| Brain Tumors | Thirty-three adult (≥18 years of age) patients with primary non-cerebellar brain tumors or metastatic tumors located in a non-cerebellar brain location who will also undergo surgery for tumor resection. This group will be included for comparison. Receives: Other: Impact of Cerebellar Functional Topography on Cognition and Motor Ataxia |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of cerebellar tumor patients with a positive cerebellar cognitive affective syndrome (CCAS) diagnosis prior to surgery
CCAS/Schmahmann syndrome scale: 120 point scale (0=most severe cognitive impairment to 120=no cognitive impairment)
Measured: Baseline
Percentage of brain non-cerebellar tumor patients with a positive cerebellar cognitive affective syndrome (CCAS) diagnosis prior to surgery
CCAS/Schmahmann syndrome scale: 120 point scale (0=most severe cognitive impairment to 120=no cognitive impairment)
Measured: Baseline
Secondary outcomes (12)
Neurological Impact of tumor location in patients undergoing resection of cerebellar tumors
"Impact" will be determined with standard of care neurological evaluation and "tumor location" with magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography
Measured: Discharge (1-2 days after surgery)
Neurological Impact of tumor location in patients undergoing resection of cerebellar tumors
"Impact" will be determined with standard of care neurological evaluation and "tumor location" with magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography
Measured: 1 month after surgery
Neurological Impact of tumor location in patients undergoing resection of cerebellar tumors
"Impact" will be determined with standard of care neurological evaluation and "tumor location" with magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography
Measured: 6 months after surgery
Neurological Impact of tumor location in patients undergoing resection of cerebellar tumors
"Impact" will be determined with standard of care neurological evaluation and "tumor location" with magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography
Measured: 12 months after surgery
Neurological Impact of tumor location in patients undergoing resection of cerebellar tumors
"Impact" will be determined with standard of care neurological evaluation and "tumor location" with magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography
Measured: 18 months after surgery
Neurological Impact of tumor location in patients undergoing resection of cerebellar tumors
"Impact" will be determined with standard of care neurological evaluation and "tumor location" with magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography
Measured: 24 months after surgery
Neurological Impact of tumor location in patients undergoing resection of brain non-cerebellar tumors
"Impact" will be determined with standard of care neurological evaluation and "tumor location" with magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography
Measured: Discharge (1-2 days after surgery)
Neurological Impact of tumor location in patients undergoing resection of brain non-cerebellar tumors
"Impact" will be determined with standard of care neurological evaluation and "tumor location" with magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography
Measured: 1 month after surgery
Neurological Impact of tumor location in patients undergoing resection of brain non-cerebellar tumors
"Impact" will be determined with standard of care neurological evaluation and "tumor location" with magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography
Measured: 6 months after surgery
Neurological Impact of tumor location in patients undergoing resection of brain non-cerebellar tumors
"Impact" will be determined with standard of care neurological evaluation and "tumor location" with magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography
Measured: 12 months after surgery
Neurological Impact of tumor location in patients undergoing resection of brain non-cerebellar tumors
"Impact" will be determined with standard of care neurological evaluation and "tumor location" with magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography
Measured: 18 months after surgery
Neurological Impact of tumor location in patients undergoing resection of brain non-cerebellar tumors
"Impact" will be determined with standard of care neurological evaluation and "tumor location" with magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography
Measured: 24 months after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2020
- Study start28 Feb 2021
- Primary completion16 May 2025
- Study completion17 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cerebellar TumorsStudies of the same condition, open and under way.
- More trials run by Duke UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 66 participants (actual)
Sponsor and investigators
- Lead sponsor
- Duke University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Allan H Friedman, MD, Principal investigator, Duke Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04463979
- Sponsor's protocol ID
- Pro00105872
- Status last verified
- May 2026
- First submitted
- 2 Jul 2020
- Last updated
- 8 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Perioperative Evaluation of Cerebellar Tumors: Impact of Cerebellar Functional Topography on Cognition and Motor Ataxia
- ClinicalTrials.gov ID
- NCT04463979
- Acronym / sponsor ID
- Pro00105872
- Conditions
- Cerebellar Tumors, Brain Tumor
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 66 participants (actual)
- Lead sponsor
- Duke UniversityUniversity, hospital or other
- Study start
- 28 Feb 2021 (actual)
- Primary completion
- 16 May 2025 (actual)
- Study completion
- 17 May 2027 (estimated)
- First posted
- 9 Jul 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a prospective, cohort study to evaluate the impact of cerebellar functional topography on perioperative outcomes related to cognition and motor ataxia in patients with cerebellar tumors.
Detailed description
Purpose of the Study: This is a prospective, cohort study to evaluate the impact of cerebellar functional topography on perioperative outcomes related to cognition and motor ataxia in patients with cerebellar tumors.
Primary Aim: The primary aim of this study is to determine if patients with a cerebellar tumor are more likely to test positive for cerebellar cognitive affective syndrome than patients with non-cerebellar tumors. This information will be used to improve perioperative assessment in patients with tumors of the cerebellum.
Secondary Aim: To determine the impact of tumor location and cerebellar functional topography on perioperative outcomes (determined by standard of care neurological evaluation and brain images) in patients undergoing resection of cerebellar tumors. This information will be used to improve perioperative assessment in patients with tumors of the cerebellum.
Study Interventions: Thirty-three adult (≥18 years of age) patients with primary cerebellar brain tumors or metastatic brain tumors located in the cerebellum who will undergo surgery for tumor resection, and 33 adult patients with primary non-cerebellar brain tumors or metastatic tumors located in a non-cerebellar brain location who will also undergo surgery for tumor resection will be included in this study. The non-cerebellar brain tumor control group will be included for comparison. Participants in this study will undergo surgical resection of their cerebellar or brain tumor (as per standard of care), as well as clinical and radiographic assessment, including: neurological physical examination (including Karnofsky Performance Scale (KPS) if conducted per Standard of Care), and magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography, prior to, immediately after, at one-month, 6-month, and 1-year follow-up status post-surgical resection. These data will also be collected at 18-month (±60 days) and 24-month (±60 days) visits post-surgery, if regular office visits with the neurosurgeon are scheduled at these two time points. Only at baseline, the following will be conducted: Brief Ataxia Rating Scale (BARS) assessment score, Cerebellar Cognitive Affective Scale (CCAS/Schmahmann syndrome) scale score, Montreal Cognitive Assessment (MoCA) assessment, and a quality of life (QoL) assessment using the SF-36 questionnaire.
Data analysis: For each test item within the CCAS there is a threshold score allowing a pass/fail determination that differentiates CCAS-positive patients from CCAS-negative patients. The primary, study endpoint is the percentage of patients with a positive CCAS diagnosis prior to surgery. The investigators will evaluate whether CCAS is preferentially seen in association with any demographic or descriptive variables (particularly tumor location in the cerebellum) using chi-squared testing unless otherwise indicated. Demographic data including sex, age at time of brain tumor diagnosis and at surgery, education level completed, and dominant writing hand will be described. The distribution of each of the following preoperative variables will also be described: presenting symptom (cognitive, motor, or vestibular), brain lesion type (newly diagnosed vs recurrent), primary tumor site, primary tumor histology, presence or absence of a systemic burden of disease, presence of hydrocephalus or previous seizure in 30 days prior to surgery, prior surgery, prior whole brain radiation or stereotactic radiosurgery, initiation of antiepileptic or steroids prior to surgery, the indication for surgery. These data will be used to compare baseline characteristic of cerebellar tumor patients with non-cerebellar brain tumor patients. All statistical analysis will be performed by the investigators using Prism 4.0 (GraphPad Software, Inc.) and Stata v10 (StataCorp Lp). Significance will be assessed at alpha = 0.05.
Risks/Benefits: There will be physical or health-related risks to the surgical resection of the patients' cerebellar tumor according to the standard of care. Risk is also involved to the extent that privacy and confidentiality may be compromised. However, every reasonable effort will be made to limit breaches of privacy and confidentiality. Participants will not benefit directly from this study. However, the results of this work will help improve the perioperative assessment of patients with tumors of the cerebellum, which may improve rehabilitation efforts in this unique patient population.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cerebellar Tumors | – | Other: Impact of Cerebellar Functional Topography on Cognition and Motor AtaxiaThirty-three adult (≥18 years of age) patients with primary cerebellar tumors or metastatic tumors located in the cerebellum who will undergo surgery for tumor resection. |
| Brain Tumors | – | Other: Impact of Cerebellar Functional Topography on Cognition and Motor AtaxiaThirty-three adult (≥18 years of age) patients with primary non-cerebellar brain tumors or metastatic tumors located in a non-cerebellar brain location who will also undergo surgery for tumor resection. This group will be included for comparison. |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Thirty-three adult (≥18 years of age) patients with primary cerebellar brain tumors or metastatic brain tumors located in the cerebellum who will undergo surgery for tumor resection, and 33 adult patients with primary non-cerebellar brain tumors or metastatic tumors located in a non-cerebellar brain location who will also undergo surgery for tumor resection will be included in this study. The non-cerebellar brain tumor control group will be included for comparison.
Key inclusion criteria (2 listed)
- ≥18 years of age
- Patients with primary cerebellar brain tumors or metastatic brain tumors located in the cerebellum who will undergo surgery for tumor resection, OR with primary non-cerebellar brain tumors or metastatic tumors located in a non-cerebellar brain location who will undergo surgery for tumor resection
Key exclusion criteria (5 listed)
- Patients under the age of 18
- Patients with intracranial pathologies (e.g. stroke, vasculitis, infection, developmental anomalies, etc.) outside of the cerebellum
- Non-oncologic cerebellar pathologies (e.g. stroke, vasculitis, infection, developmental anomalies, primary cerebellar ataxias, etc.)
- Patients who are illiterate, are blind, or do not read or understand English
- Patients with a Karnofsky Performance Status score of equal to less than 40
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Impact of Cerebellar Functional Topography on Cognition and Motor AtaxiaParticipants in this study will undergo surgical resection of their cerebellar or brain tumor (as per standard of care), as well as clinical and radiographic assessment, including: neurological physical examination (including Karnofsky Performance Scale (KPS) if conducted per Standard of Care), and magnetic resonance imaging (MRI) with or without diffusion tensor imaging (DTI)/tractography, prior to, immediately after, at one-month, 6-month, and 1-year follow-up status post-surgical resection. These data will also be collected at 18-month (±60 days) and 24-month (±60 days) visits post-surgery, if regular office visits with the neurosurgeon are scheduled at these two time points. Only at baseline, the following will be conducted: Brief Ataxia Rating Scale (BARS) assessment score, Cerebellar Cognitive Affective Scale (CCAS/Schmahmann syndrome) scale score, Montreal Cognitive Assessment (MoCA) assessment, and a quality of life (QoL) assessment using the SF-36 questionnaire. | Other | Brain Tumors, Cerebellar Tumors |
Primary outcome
Percentage of cerebellar tumor patients with a positive cerebellar cognitive affective syndrome (CCAS) diagnosis prior to surgery
Time frame: Baseline
CCAS/Schmahmann syndrome scale: 120 point scale (0=most severe cognitive impairment to 120=no cognitive impairment)
Percentage of brain non-cerebellar tumor patients with a positive cerebellar cognitive affective syndrome (CCAS) diagnosis prior to surgery
Time frame: Baseline
CCAS/Schmahmann syndrome scale: 120 point scale (0=most severe cognitive impairment to 120=no cognitive impairment)
12 secondary outcomes
Neurological Impact of tumor location in patients undergoing resection of cerebellar tumors
Time frame: Discharge (1-2 days after surgery)
Neurological Impact of tumor location in patients undergoing resection of cerebellar tumors
Time frame: 1 month after surgery
Neurological Impact of tumor location in patients undergoing resection of cerebellar tumors
Time frame: 6 months after surgery
Neurological Impact of tumor location in patients undergoing resection of cerebellar tumors
Time frame: 12 months after surgery
Neurological Impact of tumor location in patients undergoing resection of cerebellar tumors
Time frame: 18 months after surgery
Neurological Impact of tumor location in patients undergoing resection of cerebellar tumors
Time frame: 24 months after surgery
Neurological Impact of tumor location in patients undergoing resection of brain non-cerebellar tumors
Time frame: Discharge (1-2 days after surgery)
Neurological Impact of tumor location in patients undergoing resection of brain non-cerebellar tumors
Time frame: 1 month after surgery
Neurological Impact of tumor location in patients undergoing resection of brain non-cerebellar tumors
Time frame: 6 months after surgery
Neurological Impact of tumor location in patients undergoing resection of brain non-cerebellar tumors
Time frame: 12 months after surgery
Neurological Impact of tumor location in patients undergoing resection of brain non-cerebellar tumors
Time frame: 18 months after surgery
Neurological Impact of tumor location in patients undergoing resection of brain non-cerebellar tumors
Time frame: 24 months after surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2026.
- Individual participant dataSharing planned: No
Related trials for Cerebellar Tumors
Not yet recruitingPhase 1/2
DLL3 CAR-T Therapy Targeting Brain Tumors
Glioblastoma of Cerebellum
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
RecruitingPhase 2
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
Colon Cancer
Active, not recruitingObservational study
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst
RecruitingPhase 1
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Neoplasms, Brain, Glioblastoma Multiforme
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Allan H Friedman, MD principal investigator
Duke Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cerebellar Tumors and Brain Tumor, run by Duke University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 8 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of cerebellar tumor patients with a positive cerebellar cognitive affective syndrome (CCAS) diagnosis prior to surgery (time frame: Baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2026.